

7. (amended once) The antifibrillogenic agent of claim 1, wherein said peptide of Formula I is selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala (SEQ ID NO:1);
 Lys-Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:2);
 Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:3);
 Lys-Phe-Val-Phe-Phe-Ala (SEQ ID NO:4);
 Ala-Phe-Phe-Val-Leu-Lys (SEQ ID NO:5);
 Lys-Leu-Val-Phe (SEQ ID NO:6);
 Lys-Ala-Val-Phe-Phe-Ala (SEQ ID NO:7);
 Lys-Leu-Val-Phe-Phe (SEQ ID NO:8);
 Lys-Val-Val-Phe-Phe-Ala (SEQ ID NO:9);
 Lys-Ile-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:10);
 Lys-Leu-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:11);
 Lys-Phe-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:12);
 Ala-Phe-Phe-Val-Leu-Lys-NH₂ (SEQ ID NO:13);
 Lys-Leu-Val-Phe-NH₂ (SEQ ID NO:14);
 Lys-Ala-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:15);
 Lys-Leu-Val-Phe-Phe-NH₂ (SEQ ID NO:16);
 Lys-Val-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:17);
 Lys-Leu-Val-Phe-Phe-Ala-Gln (SEQ ID NO:18);
 Lys-Leu-Val-Phe-Phe-Ala-Gln-NH₂ (SEQ ID NO:19);
 His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:20);
 His-His-Gln-Lys (SEQ ID NO:23); and
 Gln-Lys-Leu-Val-Phe-Phe-NH₂ (SEQ ID NO:24).

8. (amended once) The antifibrillogenic agent of claim 1, wherein the peptide of formula I is a peptide as set forth in SEQ ID NO:2.

15. (amended once) The labeled conjugate of claim 9, wherein said peptide of Formula I is selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala (SEQ ID NO:1);
 Lys-Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:2);
 Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:3);
 Lys-Phe-Val-Phe-Phe-Ala (SEQ ID NO:4);
 Ala-Phe-Phe-Val-Leu-Lys (SEQ ID NO:5);
 Lys-Leu-Val-Phe (SEQ ID NO:6);
 Lys-Ala-Val-Phe-Phe-Ala (SEQ ID NO:7);
 Lys-Leu-Val-Phe-Phe (SEQ ID NO:8);
 Lys-Val-Val-Phe-Phe-Ala (SEQ ID NO:9);
 Lys-Ile-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:10);
 Lys-Leu-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:11);
 Lys-Phe-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:12);
 Ala-Phe-Phe-Val-Leu-Lys-NH₂ (SEQ ID NO:13);
 Lys-Leu-Val-Phe-NH₂ (SEQ ID NO:14);
 Lys-Ala-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:15);
 Lys-Leu-Val-Phe-Phe-NH₂ (SEQ ID NO:16);
 Lys-Val-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:17);
 Lys-Leu-Val-Phe-Phe-Ala-Gln (SEQ ID NO:18);
 Lys-Leu-Val-Phe-Phe-Ala-Gln-NH₂ (SEQ ID NO:19);
 His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:20);
 His-His-Gln-Lys (SEQ ID NO:23); and
 Gln-Lys-Leu-Val-Phe-Phe-NH₂ (SEQ ID NO:24).

18. (amended once) A method for the treatment of amyloidosis disorders in a patient, which comprises administering to said patient a therapeutically effective amount of a peptide of Formula I as defined in claim 1.

Applicant(s): Chalifour, *et al.*
 Filing Date: November 5, 2001

19. (amended once) A method for the treatment of amyloidosis disorders in a patient, which comprises administering to said patient a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1.

A4

20. (amended once) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of a peptide of Formula I as defined in claim 1 in association with a pharmaceutically acceptable carrier.

21. (amended once) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1 in association with a pharmaceutically acceptable carrier.

22. (amended once) A composition for *in vivo* imaging of amyloid deposits, which comprises a therapeutically effective amount of a labeled conjugate as defined in claim 9 in association with a pharmaceutically acceptable carrier.

A5

32. (amended once) A composition for inhibiting amyloidosis and/or for cytoprotection, which comprises a therapeutically effective amount of a peptide as defined in claim 31 in association with a pharmaceutically acceptable carrier.

34. (amended once) A process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming amyloid deposits, said process comprising contacting the cells *in vitro* with the peptide of Formula I as defined in claim 1.

A6

35. (amended once) The process of claim 34, wherein said peptide of Formula I or said antifibrillogenic compound causes breakdown of amyloid deposits, the deposits having been formed by said cells prior to said contact.

36. (amended once) The process of claim 34, in which the cells

37. (new) The antifibrillogenic agent of claim 1, wherein the peptide of formula I is a peptide as set forth in SEQ ID NO:3.

A7

38. (new) A process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming amyloid deposits, said process comprising contacting the cells *in vitro* with the antifibrillogenic compound as defined in claim 1 for inhibiting amyloid deposit formation.

Pursuant to 37 CFR 1.121(c)(1)(ii), a marked up version of the claims showing the changes made appears as Appendix A of this Amendment.